Related Experiment Video
Updated: Jun 2, 2026
11:02
Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
Published on: May 27, 2016
Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.
Tomohiro Sasaki1, Takeshi Hirota, Yuriko Ryokai
1Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Japan.
Drug Metabolism and Pharmacokinetics
|April 23, 2011
Summary
Genetic variations in the multidrug resistance-associated protein 3 (MRP3) gene were identified, but showed no significant impact on MRP3 function or 4-MUG pharmacokinetics in humans.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Biochemistry
Background:
- Multidrug resistance-associated protein 3 (MRP3), encoded by ABCC3, is an ATP-binding cassette transporter crucial for basolateral efflux of various substrates into the bloodstream.
- Understanding genetic variations in ABCC3 is essential for predicting drug disposition and response.
Purpose of the Study:
- To identify genetic polymorphisms in the ABCC3 gene.
- To investigate the functional impact of these polymorphisms on ABCC3 expression and MRP3 transporter activity.
- To evaluate the association between ABCC3 genotypes and the pharmacokinetics of 4-methylumbelliferone glucuronide (4-MUG) in a human population.
Main Methods:
- Identification of genetic variants in ABCC3 across three ethnic populations.
- Luciferase reporter gene assays to assess transcriptional activity.
- Quantitative measurement of ABCC3 mRNA levels in human liver samples.
- Human pharmacogenomic study involving 4-MUG administration and pharmacokinetic analysis.
Main Results:
- Sixty-one genetic variants were identified in ABCC3, including 17 novel variants, though most occurred at low frequencies.
- A specific promoter variant (-1767G>A) significantly reduced transcriptional activity in vitro.
- No significant decrease in ABCC3 mRNA levels was observed in human liver samples.
- No association was found between ABCC3 promoter genotypes and the pharmacokinetics of 4-MUG.
Conclusions:
- While ABCC3 genetic polymorphisms exist and some affect transcriptional activity in vitro, they do not appear to significantly alter ABCC3 mRNA expression in human livers or influence the pharmacokinetics of MRP3 substrates like 4-MUG.
- This study provides initial insights into the pharmacogenomic impact of ABCC3 variations, but further research is warranted to fully elucidate their clinical relevance.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...